Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?

JULIA FABBRI; JUAN PABLO ESPINOSA; PATRICIA EUGENIA PENSEL; SANDRA KARINA MEDICI; PATRICIA E PENSEL, GABRIELA ULLIO GAMBOA, JULIA FABBRI, LAURA CEBALLOS, SERGIO SANCHEZ BRUNI, LUIS ALVAREZ, DANIEL ALLEMANDI, JEAN PIERRE BENOIT, SANTIAGO D PALMA, MARÍA C ELISSONDO; JEAN PIERRE BENOIT; ELISSONDO, MARÍA CELINA

ACTA TROPICA

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2020 vol. 201

0001-706X

Neurocysticercosis is a neglected tropical disease that affects the central nervous system and is the most common cause of human epilepsy acquired in developing countries. Therapeutic failures attributed to medical managementof neurocysticercosis with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and brain tissue. The aim of the current work was to characterize and compare the brain pharmacokinetic behavior of ABZ formulated as a suspension or lipid nanocapsules (ABZLNCs) in healthy mice. The relative availability in brain tissue of the active metabolite ABZ sulphoxide increased 183% when ABZ was administered as LNCs, in relation to ABZ suspension. The parent drug was also detected fora short period of time. The bioavailability of ABZ in ABZ-LNCs treated mice increased more than 2 fold compared with ABZ suspension group. The enhanced drug brain exposure observed after administration of ABZ-LNCs to healthy mice has potential usefulness for the treatment of human neurocysticercosis.